- This investment will improve the healthcare experience for
patients, reinforcing Dassault Systèmes’ role in the industry’s
transformation
- Click Therapeutics will gain access to Dassault Systèmes’
global presence and expertise to support the development of new
therapies
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today
announced its investment in Click Therapeutics, a leader in
prescription digital therapeutics and software-enhanced drug
therapies. The transaction advances Dassault Systèmes’
transformation of the patient experience in life sciences and
healthcare through end-to-end technology solutions used across the
healthcare ecosystem.
The transaction strengthens the existing relationship between
Dassault Systèmes’ MEDIDATA brand and Click Therapeutics, helping
to improve patient engagement - post-trial through
commercialization - and advancing the Patient Experience to deliver
end-to-end technology solutions across the healthcare ecosystem.
The continued relationship and subsequent investment will set a
gold standard and unified offering for digital and pharmaceutical
clinical trials' design and execution, providing a path to
Prescription Digital Therapeutics (PDTs) and Software-Enhanced (SE)
product approvals, expanded labels for existing therapeutics, and,
ultimately, a novel pipeline for long-term, real-world evidence
generation.
MEDIDATA has virtualized clinical research, creating a unified
patient experience with integrated technology solutions. This
foundation, built on running over 8,000 active studies annually,
allows MEDIDATA, together with Click Therapeutics, to extend their
commitment to patients into real-world care, fostering improved
coordination and outcomes between patients, physicians, caregivers,
and life science manufacturers. Click Therapeutics will gain access
to Dassault Systèmes’ global presence and expertise, while both
companies will provide unparalleled support for developing PDTs and
SE products, making them available to patients.
“Digital therapeutics are beginning to transform the way
customers think about their future clinical development programs
and are providing demonstrable therapeutic benefits over drugs
alone in many cases,” said Anthony Costello, CEO, Medidata.
“Today’s investment in Click Therapeutics reflects our commitment
to this exciting technology, and our partnership with them will
enable our customers to take the fastest, most reliable path to
bringing digital therapeutics to patients, helping to build a
direct connection to patients over a life-long healthcare
journey.”
“Since the FDA shared its latest thinking on Prescription Drug
Use-Related Software in guidance, we have experienced a surge in
interest in how software can add to the benefits of medication. Now
is the time to expand treatment options for patients through
software as medicine,” said David Benshoof Klein, CEO, Click
Therapeutics. “The investment from Dassault Systèmes, the foremost
leader in virtualizing the life sciences and healthcare industry,
will enable us to continue to expand the boundaries of medicine and
develop new, cutting-edge patient solutions to advance care.”
FOR MORE INFORMATION
Digital Therapeutics (DTx) are evidence-based software
interventions designed to prevent, manage, or treat medical
conditions, used independently or alongside traditional treatments.
Prescription Digital Therapeutics (PDTs) are a subset of DTx that
offer clinically validated treatment benefits. As such, they are
regulated as medical devices, reviewed by regulatory authorities
for safety and effectiveness, and require a healthcare provider’s
prescription.
Software-enhanced (SE) drugs are drug-software
combination products designed to enhance the value of a specific
drug, built on the rigor and principles of PDTs. Software-enhanced
drugs co-package a branded medication with a digital therapeutic
that targets the unique needs of the medication and its patient
population to deliver added clinical benefit compared to the
medication alone. This creates an “SE” formulation of the drug that
offers combined therapeutic benefits in one prescription for ease
of use and optimal patient access.
About Medidata: Medidata is powering smarter treatments
and healthier people through digital solutions to support clinical
trials. Celebrating 25 years of ground-breaking technological
innovation across more than 35,000 trials and 11 million patients,
Medidata offers industry-leading expertise, analytics-powered
insights, and the largest patient-level historical clinical trial
data set in the world. More than 1 million registered users across
approximately 2,300 customers trust Medidata’s seamless, end-to-end
platform to improve patient experiences, accelerate clinical
breakthroughs, and bring therapies to market faster. A Dassault
Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is
headquartered in New York City and has been recognized as a Leader
by Everest Group and IDC. Discover more at www.medidata.com and
follow us @Medidata.
About Click Therapeutics: Click Therapeutics, Inc.
develops, validates, and commercializes software as prescription
medical treatments for people with unmet medical needs. We are
expanding the possibilities of medicine with Digital Therapeutics™
that combine clinical science with the power of software to create
a new way to treat disease.
Operating at the intersection of biology and technology, we use
a proprietary platform-based approach to therapeutic development
that leverages patient-centric design principles and innovative
AI-based technologies to deliver a unique combination of engagement
and clinical outcomes, consistently. Digital therapeutics on
Click’s platform are regulated, clinically validated prescription
mobile applications that can address diverse areas of therapeutic
need, including indications in psychiatry, neurology, oncology,
immunology, and cardiometabolic diseases.
Click Therapeutics, in collaboration with Otsuka, developed the
first prescription digital therapeutic authorized by the FDA for
the adjunctive treatment of major depressive disorder symptoms,
Rejoyn™. In October 2024, in response to FDA guidance on
prescription drug use-related software (PDURS), we launched Click
SE™ to extend our digital therapeutics platform and expertise to
the development of software-enhanced drug™ therapies that combine
software with pharmacotherapy to offer added clinically meaningful
benefit to patients.
Our commitment to advancing digital medicine means we
continually improve our platform technologies, ensuring we stay at
the forefront of cognitive, behavioral, and neuromodulatory
therapeutic innovation, to achieve the best possible outcomes for
patients. Our diverse team of innovators—spanning clinicians,
researchers, technologists, designers and more—works together to
create cutting-edge digital therapeutics, united in the mission to
transform patient care. For more information, visit
www.clicktherapeutics.com and connect with us on LinkedIn.
Connect with Dassault Systèmes on Facebook
LinkedIn YouTube
ABOUT DASSAULT SYSTÈMES
Dassault Systèmes is a catalyst for human progress. Since 1981,
the company has pioneered virtual worlds to improve real life for
consumers, patients and citizens. With Dassault Systèmes’
3DEXPERIENCE platform, 370,000 customers of all sizes, in all
industries, can collaborate, imagine and create sustainable
innovations that drive meaningful impact. For more information,
visit: www.3ds.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250318855970/en/
Press: Corporate / France Arnaud MALHERBE
arnaud.malherbe@3ds.com +33 (0) 1 61 62 87 73 North America Natasha
LEVANTI natasha.levanti@3ds.com +1 (508) 449 8097 EMEA Virginie
BLINDENBERG virginie.blindenberg@3ds.com +33 (0) 1 61 62 84 21
China Grace MU grace.mu@3ds.com +86 10 6536 2288 Japan Reina
YAMAGUCHI reina.yamaguchi@3ds.com +81 90 9325 2545 Korea Jeemin
JEONG jeemin.jeong@3ds.com +82 2 3271 6653 India Priyanka PANDEY
priyanka.pandey@3ds.com +91 9886302179
Grafico Azioni Big Tree Cloud (NASDAQ:DSY)
Storico
Da Mar 2025 a Mar 2025
Grafico Azioni Big Tree Cloud (NASDAQ:DSY)
Storico
Da Mar 2024 a Mar 2025
